Companion diagnostics for a TGFß-targeted cutting-edge therapy against invasive metastatic cancer
| Reference number | |
| Coordinator | MetaCurUm Biotech AB |
| Funding from Vinnova | SEK 2 505 937 |
| Project duration | May 2021 - September 2023 |
| Status | Completed |
| Venture | Swelife and Medtech4Health - Collaborative Projects for Improved Health |
| Call | Project that contributes to improved prevention, diagnosis, monitoring or treatment |
Important results from the project
Aim of the project was to develop methods for the analysis of biomarkers, as well as in one case analysis development of a technology that generally provides a sensitive and cost-effective analysis of biomarkers. Objective has been reached in the project and Biomarkers and analysis of biomarkers have been able to be done in clinical samples.
Expected long term effects
This is expected to be able to select the patients who have the opportunity to benefit from the drug in clinical studies and then also during treatment after possible approval.
Approach and implementation
The project has run largely according to schedule, but with a minor delay in the latter part of the project.